2cureX AB (publ) publishes Interim Report for the Second Half of 2025

The second half of 2025 has been characterised by continued execution following the restructuring of the Group and the clarification of 2cureX AB’s commercial role within precision oncology.

H2 2025 Highlights

• Continued operational execution of the restructured Group model
• Further development of the direct-to-patient access framework
• Ongoing alignment with hospital-based deployment of IndiTreat®
• Strategic Letter of Intent (LOI) entered into with PreComb Therapeutics AG
• First direct-to-patient IndiTreat® test conducted under the “Operation Twin Code” strategy
• Strengthened governance and certified adviser transition
• Continued focus on cost control and capital discipline

Strategic Developments

During H2 2025, 2cureX AB continued to refine its position as a commercial and patient-access focused company. The Company does not conduct product development or regulatory approval activities internally. Instead, it operates alongside strategic partners to support clinically appropriate access to IndiTreat®.

The direct-to-patient model has been further defined during the period. The model is designed to support newly diagnosed colorectal cancer patients in understanding and accessing IndiTreat® through collaboration with treating physicians and hospitals. It does not operate outside the healthcare system and remains aligned with clinical practice.

2cureX AB also entered into a non-binding Letter of Intent (LOI) with PreComb Therapeutics AG. The LOI outlines a framework for potential collaboration within precision oncology, including treatment guidance, data-driven insights, and potential pharmaceutical engagement. The LOI is subject to the negotiation and execution of definitive agreements.

In parallel, the Company continues to operate under its strategic agreement with 2cureX A/S (Denmark), which is responsible for development, regulatory approval including IVDR compliance, and hospital installation of IndiTreat®. Installations are expected to begin in 2026.

Financial Summary (H2 2025)

• Net sales: 0 KSEK
• Other operating income: 3 KSEK
• Operating result: -644 KSEK
• Result before tax: -659 KSEK
• Cash and bank balance at period end: 2,096 KSEK
• Earnings per share: -0.03 SEK

The Company continues to operate with limited revenues and a strong focus on cost control. Expenditures during the period primarily relate to governance, commercial planning, and partner coordination.

Dividend Distribution

Dividend distribution remains an important commitment of the Company.

As previously communicated:

• The sale of 2cureX A/S generated proceeds of approximately MSEK 5.6
• In early 2025, MSEK 2.1 was distributed to shareholders
• The remaining amount is intended to be distributed following the financial review of the Annual Report for 2025

The Board remains committed to fulfilling this distribution in a structured and transparent manner.

Outlook

Looking ahead, 2cureX AB will continue to:

• Refine and execute its commercial access model
• Support patient engagement aligned with hospital-based deployment of IndiTreat®
• Maintain strict capital discipline
• Work closely with strategic partners to ensure coordinated execution

While the Company remains in an early commercial phase, the progress made during H2 2025 represents tangible steps toward establishing a sustainable commercial role within precision oncology.

The full interim report for H2 2025 is available on the Company’s website.

Certified Adviser: Mangold Fondkommission AB